[Exclusive] Samchundang Pharm Chairman Becomes One of Korea's Top 10 Wealthiest as Shares Halve to 500,000 Won... What Happened?
Yoon Daein Ranked 10th Among Korea’s Wealthiest by Forbes
Total Assets Estimated at USD 5.9 Billion Based on March 27 Closing Price and Exchange Rate
Surpasses Park Hyeon-joo of Mirae Asset and Bom Kim of Coupang
Yoon Daein, chairman of Samchundang Pharm—whose shares, once priced at over 1 million won each as a so-called "emperor stock," plunged to the 500,000-won range within a week amid contract-related controversies—has entered the ranks of Korea’s top 10 wealthiest individuals. Ironically, this situation highlights the negative aspect of the bio industry, where stock prices are driven more by future narratives than by current earnings.
According to the financial investment industry on April 15, Chairman Yoon Daein recently ranked 10th on the list of Korea’s wealthiest individuals published by the U.S. business magazine Forbes. His total assets were estimated at 5.9 billion dollars. He surpassed Mirae Asset Group Chairman Park Hyeon-joo (12th, 4.9 billion dollars), Kakao founder Kim Beom-su (13th, 3.8 billion dollars), and Coupang Chairman of the Board Bom Kim (14th, 3.2 billion dollars). It is noteworthy that the head of a company whose share price plummeted following the controversy over the overvaluation of a generic obesity and diabetes drug contract has made it to the top of the wealth rankings.
Forbes assessed assets based on the closing market price and the KRW-USD exchange rate as of March 27. This calculation heavily reflects the market value of listed shares at that time, rather than making adjustments for intrinsic business value or liquidatable real assets.
At that point, Samchundang Pharm's share price was 1.11 million won at market close—a figure already reflecting a mix of extreme expectations and controversy. In its February 26 disclosure regarding its European contract, Samchundang Pharm stated that the confirmed payment was 30 million euros (about 5.08 billion won), but on the same day, a press release described the deal as being worth 5.3 trillion won, sparking accusations of exaggeration. On March 30, the company announced a contract for oral semaglutide in the U.S., securing milestone payments of about 100 million dollars and promoting it as an "exclusive" deal, but the term "exclusive" was omitted from the official disclosure, adding to market confusion. The Korea Exchange issued a notice on March 31, warning that Samchundang Pharm could be designated as an unfaithful disclosure company for failing to comply with fair disclosure of business performance forecasts. Subsequently, further issues such as non-disclosure of the contract counterparty and allegations of stock price manipulation emerged, causing the share price to plummet rapidly.
Ultimately, Chairman Yoon's entry into Korea’s top 10 wealthiest underscores how quickly Korean bio stocks can be revalued based on expectations and narratives. Given the complexity of technology, patents, and licensing contracts, it is difficult for ordinary investors to verify such deals directly. As a result, stock prices have overreacted to press releases, analyst comments, and keyword-driven expectations. As the Samchundang Pharm controversy grew, distrust spread not only to individual stocks but also across the bio sector as a whole, leading to a sharp decline in many stocks and a one-day drop of 5.98% in the KRX Healthcare Index.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jeon Inseok, CEO of Samchundang Pharm, is attending a press conference held at the Samchundang Pharm headquarters in Seocho-gu, Seoul on the 6th. Photo by Yonhap News
View original imageAn industry official commented, "It would be excessive to generalize the entire Korean bio sector as a bubble based solely on the Samchundang Pharm case. However, this incident succinctly demonstrates the vulnerability of the Korean bio industry, where technology value is often assessed ahead of actual earnings. If trust in disclosures and information transparency collapses, the premium can swiftly turn into a bubble controversy."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.